ELNAIS: A collaborative network on Aquatic Alien Species in Hellas (Greece)

ELNAIS is a dynamic online information platform aiming to collect and report spatial information on Aquatic Alien Species in Greek waters. It covers freshwater, marine and estuarine waters, including not only established aliens but also casual records and cryptogenic species. The ELNAIS system includes: News, List of Greek experts, Literature of findings in Greece, List of species with information on their first introduction date and source as well as photos and distribution maps. Data providers are the scientific community (publications, grey literature, and databases) as well as citizen scientists. ELNAIS provides a useful tool towards national obligations and commitments under both the European and global frameworks in respect to Non Indigenous Species (CBD, WFD, MSFD).JRC.H.1-Water Resource

Arsenic concentrations in seagrass around the Mediterranean coast and seasonal variations

Arsenic’s occurrence in the environment could be due to human activities as well as to natural sources. In this study, Posidonia oceanica and Cymodocea nodosa are collected in 84 sites around the Mediterranean basin. In addition, both seagrass are collected monthly, in two sites (Calvi in Corsica and Salammbô in Tunisia). Arsenic concentrations in C. nodosa present seasonal variations in relation with spring phytoplankton blooms. For both species arsenic concentration is higher in the vicinity of geological sources (mining), lagoon outlets and industrial activities. Moreover, Mediterranean islands (Balearic, Sardinia, Corsica, Malta, Crete and Cyprus) and the Southern basin coastline exhibit lower concentrations in Arsenic than the rest of the Mediterranean basin. The wide spread distribution of these two species would encourage their use in a global monitoring network devoted to Arsenic contamination.peer-reviewe

Frequency of family meals and food consumption in families at high risk of type 2 diabetes : the Feel4Diabetes-study

A family meal is defined as a meal consumed together by the members of a family or by having> 1 parent present during a meal. The frequency of family meals has been associated with healthier food intake patterns in both children and parents. This study aimed to investigate in families at high risk for developing type 2 diabetes across Europe the association (i) between family meals' frequency and food consumption and diet quality among parents and (ii) between family meals' frequency and children's food consumption. Moreover, the study aimed to elucidate the mediating effect of parental diet quality on the association between family meals' frequency and children's food consumption. Food consumption frequency and anthropometric were collected cross-sectionally from a representative sample of 1964 families from the European Feel4Diabetes-study. Regression and mediation analyses were applied by gender of children. Positive and significant associations were found between the frequency of family meals and parental food consumption (beta = 0.84; 95% CI 0.57, 1.45) and diet quality (beta = 0.30; 95% CI 0.19, 0.42). For children, more frequent family meals were significantly associated with healthier food consumption (boys, beta = 0.172, p < 0.05; girls, beta = 0.114, p< 0.01). A partial mediation effect of the parental diet quality was shown on the association between the frequency of family meals and the consumption of some selected food items (i.e., milk products and salty snacks) among boys and girls. The strongest mediation effect of parental diet quality was found on the association between the frequency of family breakfast and the consumption of salty snacks and milk and milk products (62.5% and 37.5%, respectively) among girls. Conclusions: The frequency of family meals is positively associated with improved food consumption patterns (i.e., higher intake of fruits and vegetables and reduced consumption of sweets) in both parents and children. However, the association in children is partially mediated by parents' diet quality. The promotion of consuming meals together in the family could be a potentially effective strategy for interventions aiming to establish and maintain healthy food consumption patterns among children

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction

Background: Current fibrinolytic therapies fail to achieve optimum reperfusion in many patients. Low-molecular-weight heparins and platelet glycoprotein IIb/IIIa inhibitors have shown the potential to improve pharmacological reperfusion therapy. We did a randomised, open-label trial to compare the efficacy and safety of tenecteplase plus enoxaparin or abciximab, with that of tenecteplase plus weight-adjusted unfractionated heparin in patients with acute myocardial infarction. Methods: 6095 patients with acute myocardial infarction of less than 6 h were randomly assigned one of three regimens: full-dose tenecteplase and enoxaparin for a maximum of 7 days (enoxaparin group; n=2040), half-dose tenecteplase with weight-adjusted low-dose unfractionated heparin and a 12-h infusion of abciximab (abciximab group; n=2017), or full-dose tenecteplase with weight-adjusted unfractionated heparin for 48 h (unfractionated heparin group; n=2038). The primary endpoints were the composites of 30-day mortality, in-hospital reinfarction, or in-hospital refractory ischaemia (efficacy endpoint), and the above endpoint plus in-hospital intracranial haemorrhage or in-hospital major bleeding complications (efficacy plus safety endpoint). Analysis was by intention to treat. Findings: There were significantly fewer efficacy endpoints in the enoxaparin and abciximab groups than in the unfractionated heparin group: 233/2037 (11.4%) versus 315/2038 (15.4%; relative risk 0.74 [95% CI 0.63-0.87], p=0.0002) for enoxaparin, and 223/2017 (11.1%) versus 315/2038 (15.4%; 0.72 [0.61-0.84], p&lt;0.0001) for abciximab. The same was true for the efficacy plus safety endpoint: 280/2037 (13.7%) versus 347/2036 (17.0%; 0.81 [0.70-0.93], p=0.0037) for enoxaparin, and 287/2016 (14.2%) versus 347/2036 (17.0%; 0.84 [0.72-0.96], p=0.01416) for abciximab. Interpretation: The tenecteplase plus enoxaparin or abciximab regimens studied here reduce the frequency of ischaemic complications of an acute myocardial infarction. In light of its ease of administration, tenecteplase plus enoxaparin seems to be an attractive alternative reperfusion regimen that warrants further study